Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta).
Matalon
Shelly Tartakover
ST
Oncogenetic Laboratory, Department of Medicine A, Sapir Medical Center, Kfar-Saba, Israel.
Ornoy
Asher
A
Lishner
Michael
M
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D001379:Azathioprine / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D023421:Models, Animal; D010920:Placenta / Q000187:drug effects; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D018675:Toxicity Tests
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D001379:Azathioprine